[HTML][HTML] Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
MA Dickson, WD Tap, ML Keohan… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
MA Dickson, WD Tap, ML Keohan, SP D'Angelo, MM Gounder, CR Antonescu, J Landa…
Journal of clinical oncology, 2013•ncbi.nlm.nih.govPurpose CDK4 is amplified in> 90% of well-differentiated (WDLS) and dedifferentiated
liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor
PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase
I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable
disease. We performed an open-label phase II study to determine the safety and efficacy of
PD0332991 in patients with advanced WDLS/DDLS.
liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor
PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase
I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable
disease. We performed an open-label phase II study to determine the safety and efficacy of
PD0332991 in patients with advanced WDLS/DDLS.
Abstract
Purpose
CDK4 is amplified in> 90% of well-differentiated (WDLS) and dedifferentiated liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS.
ncbi.nlm.nih.gov